Regeneron’s Arcalyst Gets Advisory Committee For Niche Gout Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Arthritis Advisory Committee will consider the interleukin-1 blocker for prevention of gout flares during initiation of uric-acid lowering therapy. Analysts say Arcalyst could have an easier time than Novartis’ Ilaris, which the panel felt had serious infection safety issues.